BIXTDiagnosticsglobenewswire

Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation

Sentiment:Positive (80)

Summary

BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, is proud to announce a major scientific milestone: the publication of Body Oxygen Homeostasis and Mitochondrial Function from Animal Models to Clinical Applications by Prof. Avraham Mayevsky, a key advisor to Bioxytran. This groundbreaking work dives deep into the science of oxygen regulation and mitochondrial health – revealing transformative insights that could redefine treatment for stroke, Alzheimer’s, and other critical conditions. https://link.springer.com/book/10.1007/978-3-031-94113-9

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 15, 2025 by globenewswire

Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation | BIXT Stock News | Candlesense